Balyasny Asset Management
OTLK icon

Balyasny Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Balyasny Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-688
Closed -$31K – 2247
2021
Q1 		$31K Buy
+688
New +$26.3K ﹤0.01% 1697

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Balyasny Asset Management's OTLK Position: Q2 2021 in Review

Balyasny Asset Management sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 688 shares — an estimated $31K sold.

Balyasny Asset Management first reported a position in OTLK in Q1 2021 and held it in 1 quarter. The position peaked at $31K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

  • Balyasny Asset Management reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 688 Outlook Therapeutics shares in Q2 2021, an estimated $31K.
  • Balyasny Asset Management first reported a position in Outlook Therapeutics in Q1 2021 and held it in 1 quarter.
  • Balyasny Asset Management's Outlook Therapeutics position peaked at $31K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.